文献速递骨软组织肉瘤与黑色素瘤

靶向UGCG可克服溶酶体自噬抑制耐药

Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition.
PubMed 文献 · Cancer Discov · 2023-01-01

溶酶体自噬抑制(LAI)可增强癌症治疗但易复发。多癌细胞系蛋白组学与免疫印迹显示LAI诱导脂代谢酶,脂组学显示胆固醇、鞘脂和糖鞘脂增加并伴GM1+膜微域增多。抑制UGCG可协同增强LAI细胞毒性,UGCG高表达黑色素瘤患者疾病特异性生存期显著缩短,FDA批准的UGCG抑制剂eliglustat联合LAI在同系肿瘤和耐药患者来源异种移植中显著抑制肿瘤生长并改善生存。

要点

  • LAI诱导脂代谢重塑,增加胆固醇、鞘脂和糖鞘脂及GM1+膜微域。
  • 靶向UGCG可协同增强LAI细胞毒性,UGCG过表达导致LAI耐药。
  • UGCG高表达黑色素瘤患者疾病特异性生存期显著缩短。

核心结论

  • UGCG依赖的脂质重塑驱动LAI耐药,靶向UGCG可增强LAI抗肿瘤活性且无毒性,值得开展联合抑制的临床试验。

研究设计与样本

  • 采用蛋白组学、免疫印迹和脂组学分析多癌细胞系中LAI诱导的脂代谢变化。
  • 在黑色素瘤患者中分析UGCG表达与疾病特异性生存的关系。
  • 在同系肿瘤和耐药患者来源异种移植(PDX)模型中测试eliglustat联合LAI的疗效。

主要发现

  • LAI在多癌细胞系中诱导脂代谢酶,脂组学显示胆固醇、鞘脂和糖鞘脂增加。
  • LAI诱导的脂质变化伴随质膜和溶酶体上GM1+膜微域(GMM)显著增多。
  • 抑制胆固醇/鞘脂代谢蛋白增强LAI细胞毒性,靶向UGCG协同增强LAI细胞毒性。
  • UGCG抑制减少LAI诱导的GMM并增强细胞死亡,UGCG过表达导致LAI耐药。
  • UGCG高表达黑色素瘤患者疾病特异性生存期显著缩短。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Lysosomal autophagy inhibition (LAI) with hydroxychloroquine or DC661 can enhance cancer therapy, but tumor regrowth is common. To elucidate LAI resistance, proteomics and immunoblotting demonstrated that LAI induced lipid metabolism enzymes in multiple cancer cell lines. Lipidomics showed that LAI increased cholesterol, sphingolipids, and glycosphingolipids. These changes were associated with striking levels of GM1+ membrane microdomains (GMM) in plasma membranes and lysosomes. Inhibition of cholesterol/sphingolipid metabolism proteins enhanced LAI cytotoxicity. Targeting UDP-glucose ceramide glucosyltransferase (UGCG) synergistically augmented LAI cytotoxicity. Although UGCG inhibition decreased LAI-induced GMM and augmented cell death, UGCG overexpression led to LAI resistance. Melanoma patients with high UGCG expression had significantly shorter disease-specific survival. The FDA-approved UGCG inhibitor eliglustat combined with LAI significantly inhibited tumor growth and improved survival in syngeneic tumors and a therapy-resistant patient-derived xenograft. These findings nominate UGCG as a new cancer target, and clinical trials testing UGCG inhibition in combination with LAI are warranted. SIGNIFICANCE: We discovered UGCG-dependent lipid remodeling drives resistance to LAI. Targeting UGCG with a drug approved for a lysosomal storage disorder enhanced LAI antitumor activity without toxicity. LAI and UGCG inhibition could be tested clinically in multiple cancers. This article is highlighted in the In This Issue feature, p. 247.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Jain V, Harper SL, Versace AM, et al. Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition. Cancer Discov. 2023. PMID: 36331284. doi:10.1158/2159-8290.CD-22-0535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。